Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims align with the label excerpt describing syncope associated with orthostatic blood pressure changes, but several specific assertions (therapy duration effect, regular BP monitoring, and broader susceptibility claims) are not supported by the provided label text.
Category Scores
Accurate Statements
Lacosamide can cause decreases in blood pressure related to syncope, with orthostatic blood pressure changes being associated with syncope events.
5.4 Syncope: several cases associated with changes in orthostatic blood pressure.
Unsupported Statements
The longer a patient takes lacosamide, the more likely they are to experience blood pressure changes.
No provided label section links duration of therapy to increasing likelihood of blood pressure changes.
Patients taking lacosamide should be monitored regularly for changes in blood pressure.
The provided label excerpt does not include a recommendation for regular blood pressure monitoring.
Contradictions
Important Omissions
The label excerpt specifies syncope associations with orthostatic blood pressure changes and higher doses (>400 mg/day) but does not provide general statements about SBP/DBP decreases direction, general hypotension, or general heart-rate increases; an evaluation should limit claims to 'syncope associated with orthostatic blood pressure changes' rather than broader physiologic effects.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims largely concern adverse event descriptions consistent with syncope/orthostatic blood pressure changes in the provided label excerpt, but some are extrapolated beyond the provided text (e.g., therapy-duration effects and monitoring recommendations), which could lead to inaccurate expectations.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several specific assertions are not supported by the provided label excerpts (duration effect and recommendation for regular blood pressure monitoring) and some claims broaden beyond what is explicitly stated (SBP/DBP direction, general hypotension, general heart-rate increase).
Suggested Improvement
Constrain statements to what the label excerpt explicitly supports: syncope cases associated with changes in orthostatic blood pressure (and that most syncope cases occurred with doses above 400 mg/day), and avoid recommending regular BP monitoring or asserting duration-dependent worsening unless supported by additional label sections.